AIM
SYRE icon

ABS Investment Management’s Spyre Therapeutics SYRE Stock Holding History

ABS Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Buy
+89
New +$6.5K 0.12% 97

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ABS Investment Management's SYRE Position: Q2 2026 in Review

ABS Investment Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 89 shares worth $186K. The stake represents 0.12% of the portfolio and ranks #97 among its holdings.

237 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • ABS Investment Management held 89 shares of Spyre Therapeutics worth $186K as of Q2 2026.
  • Spyre Therapeutics was a new ABS Investment Management position in Q2 2026.
  • Spyre Therapeutics made up 0.12% of ABS Investment Management's portfolio in Q2 2026, its #97 holding.
  • 237 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on ABS Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.